CoChat

A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia

Talley, N. J., Van Zanten, S. V., Saez, L. R., Dukes, G., Perschy, T., Heath, M., Kleoudis, C., Mangel, A. W. · 2001 · Alimentary Pharmacology & Therapeutics
Cited by 111

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Functional dyspepsia is characterized by upper abdominal pain or discomfort. Aim: To assess the benefit of the 5‐HT 3‐receptor antagonist alosetron in a pilot, dose‐ranging, placebo‐controlled, multicentre, randomized clinical trial. Methods: A total of 320 functional dyspepsia patients received placebo (n=81), or alosetron 0.5 mg b.d. (n=77), 1.0 mg b.d. (n=79) or 2.0 mg b.d. (n=83) for 12 weeks, followed by 1 week of follow‐up. Primary efficacy was the 12‐week average rate of adequate relief of upper abdominal pain or discomfort. Secondary endpoints assessed pain and upper gastrointestinal symptoms. Results: Twelve‐week average rates of adequate relief of pain or discomfort were 46% (95% CI: 37–54%), 55% (95% CI: 46–63%), 55% (95% CI: 47–64%) and 47% (95% CI: 38–55%) in the placebo, 0.5 mg, 1.0 mg and 2.0 mg alosetron groups, respectively. Alosetron 0.5 mg or 1.0 mg showed potential benefit over placebo for early satiety and postprandial fullness. Females showed greater responses compared to males. Patients with adequate relief had significantly (P < 0.001) greater reductions in severity and frequency of functional dyspepsia symptoms than those without adequate relief. Constipation was the most commonly reported adverse event. Conclusions: Alosetron showed potential benefit in relieving functional dyspepsia symptoms compared to placebo. Patients with adequate relief of upper abdominal pain or discomfort showed improvements in multiple functional dyspepsia symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2001.00941.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 111

Metadata

Authors
Talley, N. J., Van Zanten, S. V., Saez, L. R., Dukes, G., Perschy, T., Heath, M., Kleoudis, C., & Mangel, A. W.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2001-04
Volume
15
Issue
4
Pages
525-537
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1988306998
Cited by
111
References
5
FWCI
7.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia. https://app.cochat.ai/papers/10.1046/j.1365-2036.2001.00941.x
The paper
Talley, N. J., Van Zanten, S. V., Saez, L. R., Dukes, G., Perschy, T., Heath, M., Kleoudis, C., & Mangel, A. W. (2001). A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2001.00941.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.